Enzyme Education Other Great Stuff Full Systemic Enzymes Hybrid Systemic Enzymes Digestive Enzymes Enzymes

Seaprose-S shown effective against inflammation in study.

Tags: , ,
Posted in: Enzyme Talk, Fibrenza, Systemic Enzymes, Author: admin (June 16, 2013)

Seaprose-S has been shown to outshine even serrapeptase in a study published in PubMed.  Serrapeptase has long been used in the most effective systemic enzyme formulas. Seaprose-S has been left out of most due to its expense.  The newest enzyme in our product lineup, Fibrenza, contains both serrapeptase and Seaprose-S.  A copy of the published abstract is below.  For more information on Fibrenza or any of our other powerful systemic enzymes, including Vitalzym and Neprinol, visit our Full Systemic Enzymes hub.

Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase.
Abstract
This study was designed to compare the efficacy and safety of seaprose S and serratio-peptidase in the treatment of venous inflammatory disease. Forty patients entered the study (11 males, 29 females), mean age 54.3 years (range 30-77), mean weight 74.8 kg (range 51-96), with superficial thrombophlebitis. The trial was conducted following a controlled, between patients, randomized experimental design. Seaprose S was administered as 30 mg tablets at a daily dosage of 90 mg (one tab t.i.d.), and serratio-peptidase as 5 mg tablets, at a dose of 30 mg per day (two tabs t.i.d.), both orally, for 14 days. Twenty patients received seaprose S and 20 serratio-peptidase. The findings indicate that seaprose S was more effective and better tolerated than serratio-peptidase. Although the group of patients assigned to seaprose S had considerably more severe initial symptoms, by the end of treatment spontaneous pain was reduced 68.7% from the baseline mean score (from 3.2 to 1.0), as compared with a 63.3% reduction in the serratio-peptidase group (from 3.0 to 1.1). Pain on pressure was reduced 61.1% with seaprose S (from 3.6 to 1.4), compared to 57.6% with the reference treatment (from 3.3 to 1.4). Edema was reduced respectively 75% (from 1.6 to 0.4) and 56.2% (from 1.6 to 0.7); erythema diminished 72.4% (from 2.9 to 0.8) and 58.3% (from 2.4 to 1.0); nighttime cramps were 61.1% less (from 1.8 to 0.7) compared with 52.9% (from 1.7 to 0.8); hemorrhagic suffusion was 53.3% less (from 1.5 to 0.7) compared with 41.7% (from 1.2 to 0.7); cutaneous dystrophy was reduced by 11.1% (from 1.8 to 1.6) and 7.7% (from 1.3 to 1.2). At the end of the treatment with seaprose S efficacy was assessed as good or excellent in 85% of the cases, compared with 65% for serratio-peptidase. Seaprose S caused no adverse reactions. During serratio-peptidase treatment one patient reported diarrhea, requiring temporary dosage reduction and specific treatment. It can thus be confirmed that seaprose S was effective and well tolerated in patients with inflammatory venous diseases.


Comments

Comments are closed.

Newsletter Sign Up
Sign up for special offers and promotions.
Company
Customer Service
Get the Latest News
Read up on our blog and recent postings.
Copyright © Express Naturals. 2011. All Rights Reserved. Design by Built-